PortViewPortView
MiniMed logo

MiniMed (MMEDV) Stock Analysis

NASDAQHealthcareMedical - Instruments & Supplies

$17.70+0.00%
1-year price historyRange $17.13 – $20.00
52-week range$17.70
$15.50$21.50

Track MMEDV in your portfolio for free · Portfolio tracker

What MiniMed does

MiniMed Group, Inc. is a medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Its products include insulin delivery devices like pumps and pens, continuous glucose monitors, and related software and services. The company serves people with diabetes who require insulin therapy across more than 80 countries.

Key metrics

Market cap
$495.60M
Beta
-2.86
50-day avg
$18.72
200-day avg
$18.72
52-week high
$21.50
52-week low
$15.50
CEO
Que Thanh Dallara

ETFs linked to MMEDV

Broad-market and Healthcare sector ETFs an investor holding MiniMed is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MMEDV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze MMEDV in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for MiniMed?
MiniMed trades under the ticker MMEDV on NASDAQ.
Which exchange is MMEDV listed on?
MMEDV is listed on NASDAQ.
What sector does MiniMed operate in?
MiniMed is classified in the Healthcare sector (Medical - Instruments & Supplies industry).
How can PortView help analyze MMEDV in a portfolio?
PortView shows MMEDV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.